News › Clinical Practice, Industry News, News

Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA for Injection

July 9, 2020

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines (FHL), following glabellar (frown) line injections and lateral canthal lines (LCL), commonly known as crow’s feet. The company announced that both studies demonstrated positive efficacy results and that DaxibotulinumtoxinA for Injection was well tolerated. Additionally, the studies evaluated a range of doses and, while not powered to provide clinical significance, they provide directional guidance on the impact of dose on efficacy and duration of effect.Read more at Business Wire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
    • Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity
    • USA Payments Becomes Gold Vendor Affiliate with the American Med Spa Association
    • CVS, Eli Lilly Expand Consumer Access to GLP-1 Weight Loss Medications
Advertisement